Decoy Therapeutics (NASDAQ:DCOY) Releases Earnings Results

Decoy Therapeutics (NASDAQ:DCOY) posted its quarterly earnings data on Thursday. The company reported ($3.53) earnings per share for the quarter, FiscalAI reports. The company had revenue of $0.31 million for the quarter.

Decoy Therapeutics Stock Performance

NASDAQ:DCOY traded down $0.05 on Friday, hitting $1.00. 13,022 shares of the stock were exchanged, compared to its average volume of 759,817. The stock has a market capitalization of $2.40 million, a price-to-earnings ratio of -0.03 and a beta of 0.76. Decoy Therapeutics has a 52 week low of $0.90 and a 52 week high of $16.92. The company’s 50-day moving average price is $1.82 and its 200 day moving average price is $5.16.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Decoy Therapeutics in a research report on Wednesday, September 9th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $30.00.

About Decoy Therapeutics

Decoy Therapeutics is a biotechnology company developing messenger RNA (mRNA)-based medicines. Its technology is intended to direct the body’s cells to produce therapeutic proteins, with the goal of addressing diseases through targeted biological mechanisms. The company’s research activities focus on applying its mRNA platform to potential treatments in areas including infectious disease and oncology. Its pipeline remains centered on investigational programs, and the company’s products are subject to the development, testing and regulatory approval processes required for biotechnology therapies.